ArticlePain reports2023
Test-retest reliability of a simple bedside-quantitative sensory testing battery for chronic neuropathic pain.
Article in Pain reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Sensory Abnormalities and Pain in the Donor Sites of Radial Forearm and Fibula Free Flaps-A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Reliability of Temporal Summation of Pain in Healthy and Clinical Populations: A Systematic Review and Meta-Analysis.European journal of pain (London, England) · 2025Pooled it
- Somatosensory Function and Pain: Associations Over 12 Months Postinjury in Youth With Acute Musculoskeletal Pain.The Clinical journal of pain · 2026Article
- A new screening tool for early recognition of ATTRv polyneuropathy in clinical practice: AmyloScanJournal of neurology · 2025Article
- Assessment of Mechanical Detection Thresholds in Healthy Participants and Patients With Neuropathy: A Comparison of OptiHair2 and Aesthesiometer II.European journal of pain (London, England) · 2025Article
- Article
- Innovations in acute and chronic pain biomarkers: enhancing diagnosis and personalized therapy.Regional anesthesia and pain medicine · 2025Review
- Variability in Pain Traits Among Young Individuals with High and Low Pain Sensitivity.Journal of pain research · 2025Article
- Sense-checking the approach to quantitative sensory testing to detect chemotherapy-induced peripheral neuropathy.PloS one · 2025Article
- The intrinsic reason why complementary tests (clinical neurophysiology, neuroimaging, skin biopsy) cannot establish the diagnosis of neuropathic pain.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Feasibility and acceptability of remote administration of the cold pressor test.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Current Evidence for Biological Biomarkers and Mechanisms Underlying Acute to Chronic Pain Transition across the Pediatric Age Spectrum.Journal of clinical medicine · 2023Article
- Precision Medicine in Neuropathic Pain.Handbook of experimental pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The sensory phenotype is believed to provide information about the underlying pathophysiological mechanisms and to be used in the diagnosis and treatment of chronic neuropathic pain. However, the use of standardized quantitative sensory testing (QST) protocols is limited due to high expenditures of time and costs. Thus, a simple bedside-QST battery was recently developed showing good agreement when compared with laboratory QST. The aim of this study was to preliminary validate this bedside-QST protocol. Methods: Patients experiencing chronic pain with neuropathic features (n = 60) attended 3 visits. During the first visit, laboratory QST and bedside-QST were performed by the same trained investigator. Three hours and 3 weeks later, bedside-QST was repeated. Patients completed questionnaires regarding their pain (intensity, quality), depression/anxiety, and quality of life. Test-retest reliability and convergent/divergent validity were investigated. Results: Most of the bedside-QST parameters, including also those recommended in our first study as being indicative for sensory phenotypes, revealed a moderate to excellent test-retest reliability. Overall, results for short-term reliability and interval-scaled parameters were slightly better. Most of the bedside-QST parameters did not correlate with the depression and anxiety score, suggesting a good divergent validity. Conclusions: Bedside-QST has good criterion and divergent validity as well as reliability. This battery consists of 5 low-cost devices that can be quickly and easily used to characterize the sensory phenotype of patients with neuropathic pain. A combination of bedside-QST parameters can be used to investigate patients' subgroups with specific pathophysiological mechanisms and to identify treatment responders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.